By a therapeutic point of view, it is known that increasing ROS beyond a threshold level can inhibit cell proliferation inducing cell death, so we investigated whether cancer cells expressing mutant p53 may acquire sensitivity to pro-oxidant agents. The gene discussed is TP53; the disease is cancer.